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Abstract
Background: The objectives are to compare the effectiveness of cell phone-supported SMS
messaging to standard care on adherence, quality of life, retention, and mortality in a population
receiving antiretroviral therapy (ART) in Nairobi, Kenya.
Methods and Design: A multi-site randomized controlled open-label trial. A central
randomization centre provided opaque envelopes to allocate treatments. Patients initiating ART
at three comprehensive care clinics in Kenya will be randomized to receive either a structured
weekly SMS (’short message system’ or text message) slogan (the intervention) or current standard
of care support mechanisms alone (the control). Our hypothesis is that using a structured mobile
phone protocol to keep in touch with patients will improve adherence to ART and other patient
outcomes. Participants are evaluated at baseline, and then at six and twelve months after initiating
ART. The care providers keep a weekly study log of all phone based communications with study
participants.
Primary outcomes are self-reported adherence to ART and suppression of HIV viral load at twelve
months scheduled follow-up. Secondary outcomes are improvements in health, quality of life, social
and economic factors, and retention on ART. Primary analysis is by ‘intention-to-treat’. Sensitivity
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Open Accessanalysis will be used to assess per-protocol effects. Analysis of covariates will be undertaken to
determine factors that contribute or deter from expected and determined outcomes.
Discussion: This study protocol tests whether a novel structured mobile phone intervention can
positively contribute to ART management in a resource-limited setting.
Trial Registration: Trial Registration Number: NCT00830622
Background
The most important factor for sustainable treatment of
HIV/AIDS for individuals and programs globally is
highly consistent use of highly active antiretroviral
therapy (ART). For patients, this means adhering to
daily or twice daily medication schedules, typically at a
m i n i m u mo fa tl e a s t9 5 %o ft h et i m e ,a n df o rp r o g r a m s
this means supporting and monitoring patients to
achieve those goals [1]. The World Health Organization
and UNAIDS have outlined ambitious goals of universal
access to those in need among the 28 million people
infected with HIV globally, and include a directive to
embrace new technologies to help achieve that goal [2].
Mobile telephones have transformed telephone commu-
nications dramatically in resource limited settings. In
Kenya, mobile phones penetration has reached over 60%
and Africa has the highest rate of new uptake in the
world [3]. The reach of cellular networks among HIV
infected persons may be even higher than the general
African population since both HIV and wireless network
coverage are preferenced to areas of higher population
densities such as urban areas and transport routes.
Currently, mobile phones are used intensely in personal
lives and business transactions in the region. We there-
fore feel that structured mobile phones communications
can substantially improve clinical management of HIV
patients in resource-limited settings [4].
No previous RCTs of cell-phones for ART adherence have
been reported, thus, no systematic review is available.
This protocol outlines our proposed methods of a multi-
site randomized clinical trial (RCT) that tests if a novel
mobile phone communication intervention improves
adherence to HAART, and improves other patient
outcomes in Kenya. Patient outcomes assessed include
mortality, morbidity, quality of life, social and economic
indicators. We hypothesize that the cell phone interven-
tion may directly or indirectly improve these outcomes.
If the intervention improves HAART adherence (primary
outcome) and the drug effect (suppression of plasma
viral load), then health, quality of life, social and
economic indicators could all be consequently
improved. Since the intervention also provides an
enhanced communication link between patients and
healthcare providers, patient support may also influence
patient outcomes directly, independent of drug adher-
ence. By using intention to treat (ITT) analysis, we will
broadly assess the effect of the intervention on patient
outcomes. By using sensitivity and subgroup analyses,
we will assess the intervention effect more specifically.
Methods and Design
We registered our clinical trial with ClinicalTrials.gov
and received the number NCT00830622.
Funding
Funding was obtained through the President’s Emergency
Plan for AIDS Relief (PEPFAR) through a cooperative
agreement, #U62/PS024510, from the US Centers for
Disease Control and Prevention.
Study design
The study is a multi-site RCT. Patients will be randomized
to the cell phone (SMS) intervention group versus the
standard of care (SOC) control (no SMS) at a 1:1
allocation ratio (see Figure 1 Consort diagram).
Randomization
A project statistician generated 1:1 randomization numbers
for study arm assignments using a random number
generating program. The randomization was stratified in
a 2:2:1 ratio to the three clinics (the rural clinic having the
lower number of assignments). Written allocation of
assignment is sealed in individual opaque envelopes
marked with study identification numbers which are
distributed to all three study clinics in sufficient quantity
to allocate the target numbers of participants. After
consenting to participate and meeting inclusion criteria,
screened subjects are enrolled and immediately afterward
are assigned to the randomized study arm by a clinician
opening the sealed envelopes to determine allocation. Age,
gender, and CD4 T cell counts will be assessed for balance
of study arm allocation at each site.
Setting and participants
Subjects are recruited from three HIV comprehensive
care clinics (CCC) in Kenya. One facility is an urban
university-run clinic situated in a lower socioeconomic
area of Nairobi, the second is an urban clinic attached to
a faith-based hospital situated in a middle income area
Trials 2009, 10:87 http://www.trialsjournal.com/content/10/1/87
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situated in a vast rural district of Kenya populated by
pastoralists.
Patients are eligible to participate if they are initiating
HAART for the first time (within two weeks before or after
enrolment screening), if they are adults (at least 18 yrs
old), if they owned or had sufficient access to a mobile
phone (shared access is allowed if access is daily and the
phone owner agrees to participate), and if they were able to
sufficiently operate a cell phone to communicate using
text-messaging (help by a partner is sufficient for illiterate
subjects). Patients need to provide oral and written consent
to participate. For patients who are illiterate, clear oral
consent is obtained. Patients are excluded if they do not
meet inclusion criteria or are not planning to attend the
enrolment clinic for the planned study period (at least two
years). Patients are considered newly initiating HAART if
they have not taken HAART in at least one year and have
not taken it ever for more than 2 months. Most prevention
of mother to child transmission (PMTCT) regimens in
Kenya include limited antiretroviral regimens and not true
HAART, so participation in PMTCT is not an exclusion
criteria. Therefore, the study covers a broad range of
patients attending comprehensive care clinics (CCC) for
ART in Kenya.
Participants are compensated for their participation time
with money for lunch on study visit days (100 Kenya
shillings). Patients are not provided cell phones or network
airtime credit.
Intervention
The intervention being evaluated is a structured cell
phone initiative to improve communications between
healthcare providers and patients. The intervention
protocol was conceived in 2005 by several brainstorming
meetings between health care provider staff at the clinics,
and ultimately incorporated feedback from pilot patients
from a survey and from small group sessions [3].
Every week, on Monday mornings, the site-clinician
(typically a nurse or clinical officer) sends a text message
(SMS) to all subjects in the intervention arm to remind
them about their support and enquire into how they are
doing. Typically, a slogan is used such as “Mambo?”
which is Kiswahili for “How are you?”, but similar
slogans in other local languages can also be used at the
clinicians’ discretion. To simplify their work, the
clinicians use the ‘send to many’ function on their cell
phone for mass/group messaging. Intervention subjects
are instructed to respond within 48 hours either that they
are doing well ("Sawa”)o rt h a tt h e yh a v eap r o b l e m
("Shida”) and request assistance. Sending an SMS is
inexpensive (less than $0.05); however, in some
circumstances where network credit is not available or
was impractical, the patients can use the free ‘flashback’
function to trigger a call from the clinician. The clinician
then calls to follow-up and provide triage to any subjects
that respond that there is a problem, or subjects who fail
to respond within two days.
Clinicians are only expected to respond to text messages
during regular clinic hours, but are not restricted to do so.
Intervention participants are instructed that the interven-
tion is a clinic utility and that all emergencies should be
handled through their usual means such as attending the
nearest hospital emergency department. All participants
receive a brief training from the clinicians on use of the
phone and the protocol if they were in the intervention.
Use of any of the cell phone network providers is allowed.
Receiving SMS text messages or voice calls in Kenya is free
on all networks.
Control
Patients randomized to the control arm receive their
usual standard of care (SOC) clinic support but are not
sent the weekly SMS slogans from the clinicians. They
are, however, free to call the clinic staff at any time on
their own initiative. All cell phone communications
between clinicians and study participants, in both study
arms, are recorded in a study log.
Objectives
Primary objectives
The study is intended to test whether the cell phone
intervention (SMS) improves self-reported adherence to
HAART and whether it affects a biological surrogate marker
of adherence, specifically suppression of plasma HIV RNA
load at 12 months follow-up. We hypothesize that the SMS
intervention will remind patients taking HAART about
clinic support and reinforce regular communications in
order to sort out any adherence related problems
efficiently. Thus, we hypothesize the intervention will
positively support patients’ adherence to HAART and
consequent suppression of HIV viral load compared to
patients who only receive the standard of care (control).
Secondary objectives
Wewillalsotestthecellphoneintervention(SMS)abilityto
improve health, quality of life, social, economic outcomes
and retention in ART programs. We hypothesize that
patients who receive the weekly SMS reminders (interven-
tion) may have improved immune reconstitution (CD4
count), increased body weight, fewer opportunistic infec-
tions, fewer adverse health events, improved quality of life,
delayed death, improved social factors such as disclosure of
their HIV status, and improved economic indicators
Trials 2009, 10:87 http://www.trialsjournal.com/content/10/1/87
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(control). We also hypothesize that subjects in the
intervention arm will be more frequently retained in the
ART program.
Outcome measures
Sampling and enrolment
We determined that continuous sampling was imprac-
tical since the clinics are often extremely busy and clinic
staff are obliged to provide rapid patient care in order to
meet service targets. Only a few patients (typically up to
five) can typically undergo the consenting and enrol-
ment evaluation process daily at each site. Subjects are
not screened if they are participating in a different
adherence study, which occurs at one clinic site. To
determine the comparative characteristics of study
participants with the general clinic population, we will
compare baseline characteristics of a sample of non-
study participants with characteristics of subjects
enrolled in our study. Since mobile phone access is an
enrolment criterion, we will include comparison of
baseline characteristics of study enrolees with other
clinic attendees who do not have phone access.
Primary outcomes
The first primary outcome is patient adherence to HAART
at twelve months. (See Appendix) This is assessed by
self-report using a standard questionnaire of the number
of pills missed in the last 30 days and calculating percent
adherence based on the expected number of doses taken.
Percent adherence will be analyzed as a continuous
variable and dichotomous variable. Subjects are consid-
ered either ‘adherent’ or ‘non-adherent’ using an optimal
adherence cut off of > 95% of medications taken as
directed [1]. Adherence is assessed at each follow-up visit
and ‘ever-non-adherent’ will be our dichotomous out-
come. The twelve month scheduled follow-up (defined,
allowing for non-exact timing of clinic attendance, as
follow-up up to 15 months if patients not present at
12 months) is the primary analysis. The six month
assessment will allow for evaluating trends but is not the
primary outcome.
The second primary outcome is suppression of plasma
HIV RNA load at twelve months after initiating ART. If
patients are adherent to HAART regimens, absorb the
drugs normally, and if their virus is not resistant to the
HAART drugs in the regimen, then plasma HIV load
should be suppressed to below detectable levels (≤400
copies per ml) by six months and remain suppressed
thereafter. Due to variability in when patients show up
for scheduled appointments, we accept follow-up on or
after 20 weeks as the six month outcome visit. Analysis
of ‘suppressed’ (≤400 copies/ml) versus ‘failure’ to
suppress (>400 copies/ml) at twelve months as a
dichotomous variable is the primary analysis. However,
decrease in plasma HIV load copies from baseline to
twelve month follow-up will also be analyzed as the
difference in a continuous variable from baseline to
twelve months.
Secondary outcomes
The potential benefits of the intervention are quite
broad, so multiple secondary outcomes are of interest
and were selected through academic collaboration. The
secondary outcomes fall under the categories of health,
quality of life, social factors, and economic indicators
(see Table 1). The primary purpose of taking antiretro-
viral medications for HIV infection is to maintain or
restore health in someone who is HIV infected. Several
other factors that contribute to a subject’sp r o s p e r i t yo r
overall well-being may be affected directly (by way of
enhanced support mechanisms associated with the
intervention), or indirectly (through improvements in
health related to HAART effect). We therefore feel it is
important to assess each of these outcomes indepen-
dently.
In addition, we hypothesize that the intervention
will lead to improved retention on ART [5]. Because
participants are actively traced for twelve month follow-
up visits, we will use composite retention outcomes. We
define ‘retained’ as someone who followed-up on their
scheduled visit without being traced and is still taking
Table 1: Secondary Outcome Measures
Secondary outcome measures (6 months and
12 months post initiation of HAART)
Type
Health outcomes
Self-reported adherence as a percentage Binary
Suppressed HIV viral load (in copies) Continuous
Immune reconstitution (change in CD4 T cell count
from baseline)
Time to virological failure Continuous
Weight gain [lbs] and BMI Time-to-event
Occurrence of opportunistic infections (OIs) Continuous
Time to reporting of adverse drug events (ADEs) Binary
Deaths (all cause) Time-to-event
Quality of life (QOL) Time-to-event
SF-12
Satisfaction with care provided Continuous
Social factors Continuous
Level of disclosure of HIV status
Impression of stigma Binary
Family dyamics Continuous
Economic factors Continuous
Employment attendance
Household member school attendance Continuous
Cell phones lost/stolen Continuous
HAART = highly active antiretroviral therapy, SF-12 = short form 12
adapted for regional application in Kiswahili.
Trials 2009, 10:87 http://www.trialsjournal.com/content/10/1/87
Page 5 of 10
(page number not for citation purposes)ART versus ‘unretained’ which includes subjects who
stopped taking ART before their twelve month visit, who
are lost to follow-up, or required active tracing after
missing their scheduled twelve month appointment. We
will report each element of the composite endpoints [6].
Sample size
The primary objectives of this trial to improve adherence
to HAART and suppression of HIV viral load evaluated at
12 months. The sample size calculation is based on the
comparison between proportions of patients with
adherence rates (measured as percent of adherence
>95%) in the two groups at 12 months because this is
the variable that required the larger sample size. The
criterion for significance (alpha) has been set at 0.05.
The test is 2-tailed, which means that an effect in either
direction will be interpreted.
The sample was calculated using (Cary, NC). With the
proposed sample size of 247 and 247 for the two groups
(ie assuming a 1:1 allocation ratio), the study will have
power of 80% to yield a statistically significant result
using a chi-squared test (assuming an intention-to-treat
principle for the analysis) at alpha = 0.05/2 (ie using
the Bonferroni correction factor for the two primary
outcomes).
This computation assumes 10% improvement in ‘perfect
adherence’ over a baseline of 75% determined from rates
in a large adherence trial by AMPATH in Western Kenya
which we felt is the most representative data available [7].
This difference of 10% was selected as the smallest
difference that would be important to detect, in the sense
that any smaller difference would not be of clinical or
substantive importance. It is also assumed that this
difference is reasonable, in the sense that an effect of this
magnitude could be anticipated in this field of research.
Assuming attrition rates of approximately 10% we
intend to over-enrol by 10% resulting in an enrolment
target of at least 534 participants for randomization (267
in the Intervention, and 267 in the Control).
Data collection
Data collection tools include a baseline questionnaire,
follow-up questionnaire (used at 6 and 12 month visits),
the SF-12 quality of life assessment adapted for local
content, GPS co-ordinates of the clinics and participants
homes, and a household roster of economic indicators.
Questionnaires include continuous and categorical vari-
ables and Likert scales. All questionnaires were designed
in English and translated to Kiswahili then back
translated to verify meaning. Questionnaires are admi-
nistered by clinic staff fluent in the languages of
participants. In instances where study participants
speak only local languages, the clinician translates
questions directly. Antiretroviral adherence is assessed
at each follow-up visit by inquiring about missed doses
in the previous 30 days and calculating percent
adherence according to pill counts. A visual analogue
scale is used to confirm calculated adherence rates. A
weekly study log is kept to record the weekly SMS
messages and responses including details related to
phone access, medication adherence and health or
illness issues as they arose. Telephone communications
with subjects in the control arm are also recorded in a
similar study log, even though they are not sent the
weekly SMS messages. Clinic charts are reviewed for
WHO stages and clinical data on health parameters and
events. A study register is kept to record follow-up.
Attempts are made to obtain lab data from samples
obtained at usual clinical care time points and thus are
either collected at the same visit as the study ques-
tionnaires are administered or within two weeks if not
the same day. The CD4 T cell counts are run on a
FACScan (Becton Dickson) at a centralized site. Plasmas
for HIV viral load testing (Roche Amplicor) are separated
at the central laboratory for the Nairobi clinics, but
separated and frozen at -20C and batched for transport
from the rural district clinic. All plasmas are frozen at -
80C at the central lab. Viral loads are run in batches
using manufacturer controls.
Analysis plan
Analysis of primary and secondary outcomes
The trial will be reported according to the CONSORT
standards for reporting randomized trials. We will use
intention to treat (ITT) principles for primary outcome
analysis and conduct additional sensitivity and ‘per
protocol’ analysis separately as outlined below. Inten-
tion to treat implies all subjects randomized are
considered in outcomes as per randomization. In this
analysis we will impute missing outcome data as
treatment failures. For adherence assessment, missing
data at 12 months will be considered as ‘non-adherent’;
for viral suppression analysis, missing data at 12 months
will be considered as virologic failures. We will use
multiple imputation for imputing missing data that are
not directly related to adherence. It is considered the
gold standard for handling missing data because it leads
to unbiased estimates of the effect and standard errors
compared to single imputation methods [8].
Sensitivity Analyses
Sensitivity analysis and per-protocol analysis includes
study subjects who meet certain criteria. For sensitivity,
additional analysis of outcomes as stated above will
Trials 2009, 10:87 http://www.trialsjournal.com/content/10/1/87
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primary 12 month endpoint. Because the SMS interven-
tion protocol requires active participation of study
subjects to respond and thus conduct the intervention
as fully intended, per-protocol analyses will also be
performed. Study participants in the intervention arm
who respond to the weekly SMS’sw i t ha nS M Sb a c k
( a c t i v er e s p o n s e )a tl e a s t8 0 %o ft h et i m ew i t ht h e4 8
hour time frame will be considered highly protocol-
adherent; those who respond 50% to 80% of the time
will be considered moderately protocol-adherent; those
who respond less than 50% will be considered poorly
protocol-adherent; and those that respond less than 20%
will be considered least protocol-adherent. Subjects who
are randomized to the SMS intervention but never
respond with a return SMS, for whatever reason, will
be considered as never responding and not included in
the sensitivity analysis. We will also perform a sensitivity
analysis to assess the impact of potential clustering of
patients cared for by the same clinic.
Sub-group analyses
Because a large clinical trial on this type of intervention
has never been done before, we are interested in the
interventions effect on various subgroups and the effect
of multiple covariates on treatment outcomes. Sub-
groups of particular interests and potential covariates
proposed are outlined in Table 2. Treatment arms will be
compared with respect to potential covariates using
continuous and categorical univariate analyses.
Statistical methods
The intervention arm (SMS) will be compared against
the control (SOC) for all primary analysis. We will use
chi-squared test for binary outcomes, and T-test for
continuous outcomes. For subgroup analyses, we will
use regression methods with appropriate interaction
terms (respective subgroup × treatment group). Multi-
variable analyses will be based on logistic regression (See
Table 2) for binary outcomes and linear regression for
continuous outcomes. We will examine the residual to
assess model assumptions and goodness-of-fit. For
timed endpoints such as mortality we will use the
Kaplan-Meier survival analysis followed by multivariable
Cox proportional hazards model for adjusting for
baseline variables. We will calculate Relative Risk (RR)
and RR Reductions (RRR) with corresponding 95%
confidence intervals to compare dichotomous variables,
and difference in means will be used for additional
analysis of continuous variables. P-values will be
reported to four decimal places with p-values less than
0.001 reported as p < 0.001. Up-to-date versions of SAS
(Cary, NC) and SPSS (Chicago, IL) will be used to
conduct analyses. For all tests, we will use 2-sided
p-values with alpha = < 0.05 level of significance. We will
use the Bonferroni method to appropriately adjust
the overall level of significance for multiple primary
outcomes, and secondary outcomes.
To assess the impact of potential clustering for patients
cared by the same clinic, we will use generalized
estimating equations [GEE] (ref) assuming an exchange-
able correlation structure. Table 3 provides a summary of
methods of analysis for each variable. Professional
academic statisticians (LT, RN) blinded to study groups
will conduct all analyses.
Nested studies
Descriptors from the study logs
It is unknown what types of problems and issues will
arise as a result of the cell phone intervention initiated
by the study protocol. Detailed study logs kept by the
study clinicians will allow description of the issues raised
by patients during phone contact and how they were
handled by the clinicians in both the SMS intervention
group and standard of care control group.
Healthcare worker surveys
The nurses and clinical officers (clinicians) that manage
the SMS intervention will be asked to complete self-
administered questionnaires regarding their experiences.
They will also be asked about their time commitments
and work load before and after instituting the interven-
tion.
Qualitative interviews
Semi-structured interviews will be designed to investi-
gate in-depth experiences of subjects enrolled in the
study. Twenty participants are targeted for a balance of
gender and other characteristics such as occupation and
lifestyle. Interviews are conducted in English or KiSwa-
hili and in the latter case back-translated into English by
two separated translators.
Table 2: List of subgroups and potential covariates
Subgroups of interest Potential covariates
Urban vs. rural Age
By clinic Gender
Female vs. male Distance from clinic
Phone ownership (owned vs. shared) Income level
Occupational designation Cost to attend clinic
Level of education Level of literacy
Usual mode of transportation used Baseline quality of life
HIV staging
Level of disclosure of status
Crossover into intervention
HAART = highly active antiretroviral therapy.
Trials 2009, 10:87 http://www.trialsjournal.com/content/10/1/87
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The study is being conducted in accordance with the
Helsinki declaration and established guideline for
research on human subjects. The study protocol was
approved by the University of Manitoba and Kenyatta
National Hospital ethics review boards. All participants
provide written consent. This study does not have a Data
and Safety Monitoring Board. We do not have a code-
breaking procedure for randomization as the study is
unblinded, except for analysis. All protocol amendments
Table 3: Variables, Measures and Methods of Analysis
Variable/Outcome Hypothesis Outcome Measure Methods of Analysis
1) Primary Intervention improved
outcome from baseline
to 6 months
a) Adherence at 12 months Percent adherence in previous 30 days
>95% [binary]
Chi-squared test
b) Suppression of HIV viral load at 12 months Viral load ≤400 copies/ml [binary] Chi-squared test
2) Secondary
Adherence percentage at 12 months
improvement occurred Adherence % (>95%) [binary] Chi-squared test
HIV viral load at 12 months improvement occurred Viral load (copies) T-test
Immune reconstitution (change in CD4 T cell
count from baseline)
improvement occurred Cd4 T-cells/mm
3 (continuous) T-test
Time to virological failure Improvement occurred Virological failure after successful
suppression
Kaplan-Meier survival
analysis
Weight gain [lbs] and BMI improvement occurred Change in weight (lbs) and BMI
[continuous]
T-test
Occurrence of opportunistic infections (OIs) improvement occurred Presence of AIDS defining
opportunistic infection [binary]
Chi-squared test
Time to reporting of adverse drug events (ADEs) improvement occurred Presence of drug-related adverse event
[time to event]
Kaplan-Meier survival
analysis
Deaths (all cause) improvement occurred All-cause mortality [binary] Chi-squared test and Kaplan-
Meier survival analysis
SF-12 improvement occurred Quality pf life questionnaire
[continuous]
T-test
Satisfaction with care provided improvement occurred Questionnaire [continuous] T-test
Level of disclosure of HIV status improvement occurred Disclosed to a family member [binary] Chi-squared test
Impression of stigma improvement occurred Questionnaire [continuous] T-test
Family dyamics improvement occurred Questionnaire [continuous] T-test
Employment attendance improvement occurred Questionnaire [continuous] T-test
Household member school attendance improvement occurred Questionnaire [continuous] T-test
Cell phones lost/stolen improvement occurred Presence of cellphone [binary] Poisson regression
Stopped taking HAART improvement occurred Self-report [binary] Chi-squared test
Required active tracing for 12 month follow-up improvement occurred Field officers [binary] Chi-squared test
3) Subgroup Analyses: Regression methods with
appropriate interaction term
Urban vs. rural Distance affects
adherence
Female vs. male Sex affects adherence
Phone ownership (owned vs. shared) Ownership affects
adherence
Level of education Low education affects
adherence
4) Sensitivity Analyses: improvement occurred All outcomes
a) Per protocol analysis a) Chi-squared/T-test test
b) Adjusting for baseline covariates b) Multivariable regression
c) clustering among individuals within a clinic c) GEE
IMPORTANT REMARKS:
￿ The GEE [11] is a technique that allows to specify the correlation structure between patients within a hospital and this approach produces unbiased
estimates under the assumption that missing observations will be missing at random. An amended approach of weighted GEE will be employed if
missingness is found not to be at random [12].
￿ In all analyses results will be expressed as coefficient, standard errors, corresponding 95% and associated p-values.
￿ Goodness-of-fit will be assessed by examining the residuals for model assumptions and chi-squared test of goodness-of-fit.
Bonferroni method will be used to adjust the overall level of significance for multiple secondary outcomes.
Trials 2009, 10:87 http://www.trialsjournal.com/content/10/1/87
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(RTL, JK, LG, and FP). The investigators have no
competing interests. We will not provide post-trial care
using SMS until approval from the ART funding body.
All study results will be publicly available.
Discussion
The intervention being tested provides the opportunity
to improve health care delivery in resource limited
settings. Our study is one of several planned randomized
trials evaluating cell-phone based technology for adher-
ence. In other settings, Collier et al. demonstrated that an
intensive regular telephone-based adherence counselling
intervention did not significantly improve adherence to
H A A R Ti nt h eU n i t e dS t a t e s ,I t a l y ,a n dP u e r t oR i c o[ 8 ] .I n
a separate randomized trial in the United States, a
structured telephone counselling intervention did
improve adherence to HAART and there was a trend
toward improved clinical outcomes [9]. A recently
piloted SMS text reminder to improve adherence to
ART among Los Angeles youths was acceptable and
showed early benefit on adherence [10]. In another
study, a structured cell phone intervention to help HIV
patients attending an inner-city clinic in Texas quit
smoking was highly successful [10]. We feel that the
benefits of mobile telephony in resource limited settings
may be greater than in countries with developed
economies, since they are more widely used in manage-
ment of daily life activities, and mark a great contrast to
pre-mobile phone era communication infrastructures.
Additionally, our study is unique in that it focuses on a
simple structured SMS protocol without a specified
counselling intervention. Thus we are directly testing
the ability for improved, efficient communications to
have an impact on patient care.
The multi-site randomized controlled trial design was
specifically designed to incorporate a broad sampling of
populations attending ART care clinics in Kenya. This
approach risks diluting the statistical power to detect
treatment responses which could be more easily seen in
more homogenous patient groups. However, we feel
there is a common thread of impact of cell phone usage
across all populations in the region. This study design
and analysis plan will allow us to evaluate several factors
that may contribute a variable array of patient benefits.
We are also aware that by consenting and participating in
this study, both the healthcare providers and study
subjects (including controls), are made more aware of
the potential benefits of increased cell phone commu-
nications even outside the SMS protocol. This is known
as the Hawthorne effect of participation in clinical trials,
and may reduce the power to compare the effect of the
SMS intervention against the true standard of care seen
in non-study environments. Since it would be unethical
to restrict communications between health care provi-
ders and patients, we have applied for ethics approval to
compare adherence and other outcomes in this clinical
trial with non-trial participants at the same or similar
clinics. We recognize that blinding participants in a trial
such as ours is impossible. However, our SMS texts are
delivered in such a way as to a) reduce likelihood of
disclosure to others around the patient and b) to act as a
reminder of health, rather than HIV status, as our texts
simply state ‘how are you?’
All factors contributing to the success or failure of the
intervention to improve health care management of
patients are unlikely to have been predicted ap r i o r i .
Therefore the results of this trial, including the qualita-
tive nested studies and experiences of participating
clinicians, will not only test the effectiveness of the
described intervention protocol, but will instruct further
d e v e l o p m e n to ft h eu s eo fm o b i l et e l e p h o n yt oi m p r o v e
health management in resource limited settings.
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Appendix
Primary Outcome Measures
HAART = highly active antiretroviral therapy.
Primary binary outcomes (12 months post initiation of
HAART)
1. Self-reported adherence (>95%) in previous 30
days)
2. Suppressed HIV viral load (≤400 copies/ml)
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